Pint Pharma International S.A.

BioCryst Pharmaceuticals, Inc. ’s launch numbers for Orladeyo (berotralstat) have beat expectations, and the North Carolina-based firm says its drug – the first oral prophylaxis for hereditary angioed

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . AstraZeneca Calls On Cheplap

In an unusual move, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has changed its mind on the merits of a product that it had originally said should not b

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in